Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Operating Margin: 2020-2025

Historic Operating Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to 48.67%.

  • Apellis Pharmaceuticals' Operating Margin rose 7269.00% to 48.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.91%, marking a year-over-year increase of 3914.00%. This contributed to the annual value of -21.11% for FY2024, which is 10928.00% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Operating Margin stood at 48.67% for Q3 2025, which was up 360.98% from -18.65% recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Operating Margin peaked at 2,984.22% during Q1 2021, and registered a low of -31,185.71% during Q2 2021.
  • Over the past 3 years, Apellis Pharmaceuticals' median Operating Margin value was -36.03% (recorded in 2024), while the average stood at -73.29%.
  • Its Operating Margin has fluctuated over the past 5 years, first slumped by 3,285,756bps in 2021, then surged by 3,027,514bps in 2022.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Operating Margin stood at -148.29% in 2021, then slumped by 57,559bps to -723.88% in 2022, then spiked by 66,614bps to -57.74% in 2023, then spiked by 4,543bps to -12.31% in 2024, then spiked by 7,269bps to 48.67% in 2025.
  • Its Operating Margin was 48.67% in Q3 2025, compared to -18.65% in Q2 2025 and -49.96% in Q1 2025.